clinical trial · NCT07536061
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Huntington's DiseaseSRP-1005Placebo
brief summary
This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).
started
May 5, 2026
primary completion
Nov 30, 2027
completion
Nov 30, 2027
last updated
Apr 17, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Effect of SRP-1005 in Subjects With Huntington's Disease (INSIGHTT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol